Myokardia Inc (NASDAQ:MYOK) insider Joseph Lambing sold 5,000 shares of the stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the transaction, the insider now owns 95,846 shares in the company, valued at approximately $4,792,300. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Myokardia Inc (NASDAQ MYOK) opened at $52.90 on Friday. The stock has a market capitalization of $1,879.98, a P/E ratio of -69.60 and a beta of 4.21. Myokardia Inc has a 12 month low of $10.55 and a 12 month high of $54.00.
Myokardia (NASDAQ:MYOK) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.42). The firm had revenue of $5.63 million for the quarter, compared to the consensus estimate of $6.10 million. Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The firm’s quarterly revenue was up 58.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) EPS. analysts forecast that Myokardia Inc will post -1.62 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. Hamilton Lane Advisors LLC grew its stake in Myokardia by 134.3% during the 4th quarter. Hamilton Lane Advisors LLC now owns 92,785 shares of the biotechnology company’s stock worth $3,906,000 after buying an additional 53,186 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Myokardia by 16.9% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 94,358 shares of the biotechnology company’s stock worth $3,973,000 after buying an additional 13,640 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Myokardia in the 3rd quarter valued at approximately $1,478,000. Cubist Systematic Strategies LLC purchased a new position in shares of Myokardia in the 3rd quarter valued at approximately $355,000. Finally, RTW Investments LP purchased a new position in shares of Myokardia in the 3rd quarter valued at approximately $10,882,000. Hedge funds and other institutional investors own 63.61% of the company’s stock.
A number of research analysts have recently commented on MYOK shares. Zacks Investment Research downgraded Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. ValuEngine downgraded Myokardia from a “hold” rating to a “sell” rating in a report on Friday, December 1st. TheStreet downgraded Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. BidaskClub upgraded Myokardia from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. Finally, JPMorgan Chase & Co. started coverage on Myokardia in a report on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $55.67.
TRADEMARK VIOLATION NOTICE: “Myokardia Inc (MYOK) Insider Sells $250,000.00 in Stock” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/19/myokardia-inc-myok-insider-sells-250000-00-in-stock.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.